Oriahnn (copackaged) Patent Expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6872728 ABBVIE Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
Jan, 2021

(3 years ago)

US7462625 ABBVIE Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
Jan, 2021

(3 years ago)

US7056927 ABBVIE Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
Sep, 2024

(a month from now)

US7419983 ABBVIE Gonadotropin-releasing hormone receptor antagonists and methods related thereto
Jul, 2029

(4 years from now)

US11542239 ABBVIE Elagolix sodium compositions and processes
Jul, 2039

(15 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7179815 ABBVIE Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
Mar, 2021

(3 years ago)

US11459305 ABBVIE Processes for the preparation of uracil derivatives
Nov, 2028

(4 years from now)

US11045470 ABBVIE Methods of treating heavy menstrual bleeding
Mar, 2034

(9 years from now)

US10881659 ABBVIE Methods of treating heavy menstrual bleeding
Mar, 2034

(9 years from now)

US11690845 ABBVIE Methods of administering elagolix
Aug, 2040

(16 years from now)



Oriahnn (Copackaged) is a drug owned by Abbvie Inc. It is used for managing heavy menstrual bleeding associated with uterine leiomyomas (fibroids) with the use of elagolix and omeprazole. Oriahnn (Copackaged) uses Elagolix Sodium,Estradiol,Norethindrone Acetate; Elagolix Sodium as an active ingredient. Oriahnn (Copackaged) was launched by Abbvie in 2020. It is is available in capsule form for oral use. Its generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Aug 27, 2040 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 29, 2023
New Chemical Entity Exclusivity(NCE) Jul 23, 2023

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE; ELAGOLIX SODIUM ingredient

NCE-1 date: 23 July, 2022

Market Authorisation Date: 29 May, 2020

Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids); Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) using 300 mg elagolix while c...

Dosage: CAPSULE

How can I launch a generic of ORIAHNN (COPACKAGED) before it's drug patent expiration?
More Information on Dosage

ORIAHNN (COPACKAGED) family patents

Family Patents